TELA Bio, Inc. TELA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 19.29M | 19.06M | 20.87M | 20.69M | 20.20M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.29M | 19.06M | 20.87M | 20.69M | 20.20M |
| Cost of Revenue | 5.25M | 6.44M | 7.02M | 6.63M | 6.00M |
| Gross Profit | 14.04M | 12.62M | 13.85M | 14.06M | 14.20M |
| SG&A Expenses | 20.50M | 20.70M | 18.27M | 19.18M | 20.98M |
| Depreciation & Amortization | 95.00K | 95.00K | 95.00K | 95.00K | 95.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.57M | 29.59M | 27.52M | 28.24M | 29.28M |
| Operating Income | -9.28M | -10.53M | -6.65M | -7.55M | -9.08M |
| Income Before Tax | -11.20M | -12.21M | -8.90M | -8.60M | -9.89M |
| Income Tax Expenses | 60.00K | 60.00K | 145.00K | -- | 33.00K |
| Earnings from Continuing Operations | -11.26M | -12.27M | -9.04M | -8.60M | -9.92M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.26M | -12.27M | -9.04M | -8.60M | -9.92M |
| EBIT | -9.28M | -10.53M | -6.65M | -7.55M | -9.08M |
| EBITDA | -9.02M | -10.26M | -6.42M | -7.31M | -8.81M |
| EPS Basic | -0.20 | -0.21 | -0.17 | -0.19 | -0.22 |
| Normalized Basic EPS | -0.12 | -0.13 | -0.10 | -0.12 | -0.14 |
| EPS Diluted | -0.20 | -0.21 | -0.17 | -0.19 | -0.22 |
| Normalized Diluted EPS | -0.12 | -0.13 | -0.10 | -0.12 | -0.14 |
| Average Basic Shares Outstanding | 57.41M | 57.26M | 51.68M | 45.42M | 45.37M |
| Average Diluted Shares Outstanding | 57.41M | 57.26M | 51.68M | 45.42M | 45.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |